Preparation and use of superior vaccines

• US 20020151515A1
• Filed: 11/05/2001
• Published: 10/17/2002
• Est. Priority Date: 06/18/1999
• Status: Abandoned Application

• Current Assignee: Bruce L. Roberts
• Original Assignee: Bruce L. Roberts
• Inventors: Roberts, Bruce L.
• Application Number:
  US10/033,145
• Publication Number:
  US 20020151515A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 2039/5154 Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
• CPC Class Codes: A61K 2039/5156 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: C07K 14/523 Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

This invention provides an isolated population of polynucleotides comprising or corresponding to at least one polynucleotide shown in Table 1 and their respective complements. It also provides a polynucleotide encoding a ligand or antibody or engineered protein that binds to a cell surface protein of an antigen presenting cell and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement. The invention further provides a polynucleotide that encodes a transcription factor and wherein the polynucleotide comprises or corresponds to a polynucleotide shown in Table 1 or its complement.

Claims

1. A polynucleotide comprising of a first polynucleotide comprising encoding an immunostimulatory factor that is differentially expressed in an antigen presenting cell and comprising or corresponding to a tag shown in Table 1 or its complement, wherein the first polynucleotide encodes a factor selected from the group consisting of PARC, TARC, monocyte chemoattractant protein-4 (MDP-4), MDC, escalatin, MCP-2 or biologically active fragments thereof.

2. The polynucleotide of claim 1 further comprising a first and second promoter, wherein the first and second polynucleotides are under the transcriptional control of the first and second promoters, respectively.

3. The polynucleotide of claim 1 further comprising a first and second promoter, wherein the first and second polynucleotides are under the transcriptional control of the single promoter.

4. A gene delivery vehicle comprising a polynucleotide of claim 1.

5. A host cell that comprises a polynucleotide of claim 1.

6. An array of probes comprising a polynucleotide of claim 1 bound to a chip.

11. A method for inducing an immune response in a subject comprising administering an effective amount of the polynucleotide of claim 1, to the subject.

12. A method of modulating the genotype of an antigen presenting cell, comprising introducing into the cell a polynucleotide of claim 1.

7. A polynucleotide comprising a first polynucleotide comprising encoding an immunostimulatory factor that is differentially expressed in an antigen presenting cell and comprising or corresponding to a tag shown in Table 1 and a second polynucleotide that modulates the expression of the first polynucleotide, wherein the first polynucleotide encodes PARC, monocyte chemoattractant protein-4 (MDP-4), MDC, escalectin, MCP-2 or biologically active fragments thereof.

8. A polynucleotide of claim 7, wherein said second polynucleotide modulates the expression of a third polynucleotide which encodes an immunostimulatory factor that is differentially expressed in an antigen presenting cell, wherein the third polynucleotide comprises or corresponds to a tag shown in Table 1.

9. A gene delivery vehicle comprising the polynucleotides of claim 7.

10. A host cell comprising the polynucleotides of claim 7.